WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: TP Kidney Transplant Astagraf XL Cmap 20131126, Kidney Transplant Patients have Renal Function, CMV may be Positive, Kidney Transplant Patients have HLA-DR Type, Viral Status at Baseline includes HBV, Kidney Transplant Patients take Treatment, Calcineurin Inhibitor (CNI) may lead to Lymphoma, Renal Function assessed through analysis of Long Term Dialysis, Dosage Form administered Oraly, Exposure Related Toxicities such as Nephrotoxicity, BPAR calculate Event Rate Within First 24 months post transplantation, Calcineurin Inhibitor (CNI) are associated with Exposure Related Toxicities, Renal Function assessed through analysis of Creatinine Clearance, Calcineurin Inhibitor (CNI) may lead to Hyperlipidema, EBV may be Positive, Demographics include Race, Graft Loss is the inverse of Graft Survival, Gender can be Male, Pharmacokinetic Response was linear From 1.5 mg to 10 mg (equivalent to doses upto 2.0 mg/kg) in Healthy Subjects, Viral Status at Baseline includes HCV, Discontinue Treatment due to Excl/Incl Violation